These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26100178)

  • 1. Triple therapy vs. dual bronchodilator therapy for chronic obstructive pulmonary disease: Is it worth the cost?
    Horita N; Kaneko T
    Respir Investig; 2015 Jul; 53(4):173-5. PubMed ID: 26100178
    [No Abstract]   [Full Text] [Related]  

  • 2. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
    Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple therapy for chronic obstructive pulmonary disease: trials catching up with clinical practice?
    Jones PW
    Am J Respir Crit Care Med; 2009 Oct; 180(8):689-90. PubMed ID: 19805796
    [No Abstract]   [Full Text] [Related]  

  • 4. A pragmatic approach to simplify inhaler therapy for COPD.
    Lipworth B; Jabbal S
    Lancet Respir Med; 2017 Sep; 5(9):679-681. PubMed ID: 28693987
    [No Abstract]   [Full Text] [Related]  

  • 5. COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV
    Pavord ID
    Chest; 2018 Apr; 153(4):782-784. PubMed ID: 29410364
    [No Abstract]   [Full Text] [Related]  

  • 6. Triple inhalers for obstructive airways disease: will they be useful?
    Barnes PJ
    Expert Rev Respir Med; 2011 Jun; 5(3):297-300. PubMed ID: 21702649
    [No Abstract]   [Full Text] [Related]  

  • 7. POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV
    Chalmers JD
    Chest; 2018 Apr; 153(4):778-782. PubMed ID: 29474807
    [No Abstract]   [Full Text] [Related]  

  • 8. Switching treatments in COPD: implications for costs and treatment adherence.
    Braido F; Lavorini F; Blasi F; Baiardini I; Canonica GW
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2601-8. PubMed ID: 26664108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drugs for chronic obstructive pulmonary disorder].
    Bakke PS; Høines KJ
    Tidsskr Nor Laegeforen; 2019 Oct; 139(14):. PubMed ID: 31592602
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combined inhaled corticosteroid and long-acting beta-2-agonist in one inhaler in the treatment of chronic obstructive pulmonary disease].
    Pedersen ST
    Ugeskr Laeger; 2005 Jun; 167(23):2504-6. PubMed ID: 16008004
    [No Abstract]   [Full Text] [Related]  

  • 11. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
    Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL; Baker EL; Coleman CI
    Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COUNTERPOINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? No.
    Barrecheguren M; Miravitlles M
    Chest; 2018 Oct; 154(4):749-751. PubMed ID: 30290926
    [No Abstract]   [Full Text] [Related]  

  • 14. How do we critically use long-acting muscarinic receptor antagonists and beta-adrenergic receptor agonists monotherapy, or these combination therapies depending on the situation in Japanese patients with COPD?
    Kawayama T; Sasaki J
    Respir Investig; 2017 Nov; 55(6):323-325. PubMed ID: 29153411
    [No Abstract]   [Full Text] [Related]  

  • 15. Trend of cost and utilization of COPD medication in Korea.
    Lee J; Lee JH; Kim JA; Rhee CK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():27-33. PubMed ID: 28031708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Other forms of bronchodilation].
    Izquierdo Alonso JL; Malo de Molina R
    Arch Bronconeumol; 2004 Mar; 40 Suppl 1():23-9. PubMed ID: 16137446
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment Options for Stable Chronic Obstructive Pulmonary Disease: Current Recommendations and Unmet Needs.
    Yawn BP; Kim V
    Cleve Clin J Med; 2018 Feb; 85(2 Suppl 1):S28-S37. PubMed ID: 29494330
    [No Abstract]   [Full Text] [Related]  

  • 18. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
    Dalon F; Roche N; Belhassen M; Nolin M; Pegliasco H; Deslée G; Housset B; Devillier P; Van Ganse E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1839-1854. PubMed ID: 31692478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management--inhaled treatment.
    Currie GP; Lipworth BJ
    BMJ; 2006 Jun; 332(7555):1439-41. PubMed ID: 16777889
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhaled steroids and outcomes in COPD: progressing beyond FEV1.
    Sutherland ER
    Chest; 2007 Mar; 131(3):648-9. PubMed ID: 17356076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.